Line 3 – Translational clinical research and innovative oncological therapies

Line 3 – Translational clinical research and innovative oncological therapies


A characterizing and priority element of the IOV research is the conduct of innovative clinical studies on precision and translational medicine. Retrospective, observational, translational and interventional studies aimed both at optimizing the treatments already available and at the development of innovative therapies based on molecular characterization and precision medicine are also crucial for producing knowledge on the optimal treatment of patients. Another essential element is the search for predictive and prognostic factors and the use of patient reported outcomes (PROs) that evaluate the impact of new therapies on the quality of life of patients.


The IOV was characterized by a continuous commitment to the direct promotion and adherence to clinical protocols for pharmacological and non-pharmacological research. The results obtained to date have made it possible to develop and promote cutting-edge skills in the conception, coordination and management of clinical and translational research initiatives. The collaboration with many Italian oncologies guarantees a competitive enrollment in international trials with innovative drugs. In the oncology field, the rapid transfer of innovative therapies to the patient’s bed guarantees many patients to benefit from new treatment opportunities in real time. The results obtained must be measured and monitored with retrospective protocols which are a valuable source of data for exploratory hypotheses to be verified longitudinally. Clinical research is the point of arrival and departure of translational projects, and is intimately related to the other lines of research of the IOV.


The constant implementation of new clinical research has a strategic value with immediate repercussions on the patient (from the moment they enter the study), on the experience of individual researchers and research groups (from the moment of conception), on the scientific community (on presentation and publication of results). Clinical research is inherent in the mission of an IRCCS. The strategic objective is to implement translational research, and to identify predictive indicators of response to optimize the type and duration of innovative therapies (eg. Immunotherapy), in order to guarantee effective and socially sustainable treatments. These aspects cannot be separated from a 360 ° vision of the patient, in which prevention, rehabilitation, the nursing, psychological role, support, nutritional, pain and quality of life therapies find the right integration in research programs designed with methodological rigor as is the case for clinical trials.

Global Goals

  • Development of non-profit studies, in particular for orphan diseases (eg glioblastoma).
  • Analysis, through liquid biopsy and / or extensive molecular structure on the tumor tissue, of the characteristics of the tumor, for the search for new prognostic / predictive factors.
  • Study of the tumor microenvironment and the interaction between host and tumor.
  • Implementation and participation in real life studies, and the impact of multidisciplinary patient care, evaluating the medium and long-term outcomes (including patient satisfaction).
  • Participation in innovative international clinical trials, particularly in the early phase.

Expected and measurable results over the three-year period

  • Increase of at least 20% in the number of clinical trials active in the multicentre setting with the function of coordinator.
  • Development of at least 3 multicentre independent research study proposals with coordinator function, implementation and coordination of at least 3 international initiatives.
  • Promotion as coordinator of at least 5 translational studies and non-pharmacological studies, also oriented to the detection of predictive indicators of response and use of PROs as a quality of life parameter.

Top 15 pubblicazioni linea 3 anno 2023
TitoloTestataIF grezzoAutori
Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 studyLANCET168,90Arvind Dasari, Lonardi Sara, Rocio Garcia-Carbonero, Elena Elez, Takayuki Yoshino, Alberto Sobrero, James Yao, Pilar García-Alfonso, Judit Kocsis, Antonio Cubillo Gracian, Andrea Sartore-Bianchi, Taroh Satoh, Violaine Randrian, Jiri Tomasek, Geoff Chong, Andrew Scott Paulson, Toshiki Masuishi, Jeremy Jones, Tibor Cs?Szi, Chiara Cremolini, Francois Ghiringhelli, Ardaman Shergill, Howard S Hochster, John Krauss, Ali Bassam, Michel Ducreux, Anneli Elme, Laurence Faugeras, Stefan Kasper, Eric Van Cutsem, Dirk Arnold, Shivani Nanda, Zhao Yang, William R Schelman, Marek Kania, Josep Tabernero, Cathy Eng
Pregnancy After Breast Cancer in Young BRCA Carriers: An International Hospital-Based Cohort StudyJAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION120,70Matteo Lambertini, Eva Blondeaux, Elisa Agostinetto, Anne-Sophie Hamy, Hee Jeong Kim, Dieci Maria Vittoria, Luca Boni, Ann H. Partridge, Brca Bcy Collaboration
New options for late-line treatment of metastatic colorectal cancerNATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY65,10Lonardi Sara, Filippo Pietrantonio
Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancerANNALS OF ONCOLOGY50,50G. Villacampa, N.M. Tung, S. Pernas, L. Paré, C. Bueno-Muiño, I. Echavarría, S. López-Tarruella, M. Roche-Molina, M. Del Monte-Millán, M. Marín-Aguilera, F. Brasó-Maristany, A.G. Waks, T. Pascual, O. Martínez-Sáez, A. Vivancos, Pierfranco Conte, Guarneri Valentina, M. Vittoria Dieci, Griguolo Gaia, J. Cortés, A. Llombart-Cussac, M. Muñoz, M. Vidal, B. Adamo, A.C. Wolff, A. Demichele, P. Villagrasa, J.S. Parker, C.M. Perou, A. Fernandez-Martinez, L.A. Carey, E.A. Mittendorf, M. Martín, A. Prat, S.M. Tolaney
Different prognostic values of KRAS exon 2 submutations and BRAF V600E mutation in microsatellite stable (MSS) and unstable (MSI) stage III colon cancer: an ACCENT/IDEA pooled analysis of seven trialsANNALS OF ONCOLOGY50,50J. Taieb, F.A. Sinicrope, L. Pederson, Lonardi Sara, S.R. Alberts, T.J. George, G. Yothers, E. Van Cutsem, L. Saltz, S. Ogino, R. Kerr, T. Yoshino, R.M. Goldberg, T. André, P. Laurent-Puig, Q. Shi
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatmentANNALS OF ONCOLOGY50,50Loibl S, André F, Bachelot T, Barrios CH, Bergh J, Burstein HJ, Cardoso MJ, Carey LA, Dawood S, Del Mastro L, Denkert C, Fallenberg EM, Francis PA, Gamal-Eldin H, Gelmon K, Geyer CE, Gnant M, Guarneri V, Gupta S, Kim SB, Krug D, Martin M, Meattini I, Morrow M, Janni W, Paluch-Shimon S, Partridge A, Poortmans P, Pusztai L, Regan MM, Sparano J, Spanic T, Swain S, Tjulandin S, Toi M, Trapani D, Tutt A, Xu B, Curigliano G, Harbeck N
Transcriptome analysis reveals tumor microenvironment changes in glioblastomaCANCER CELL50,30Youri Hoogstrate, Kaspar Draaisma, Santoesha A. Ghisai, Levi Van Hijfte, Nastaran Barin, Iris De Heer, Wouter Coppieters, Thierry P.P. Van Den Bosch, Anne Bolleboom, Zhenyu Gao, Arnaud J.P.E. Vincent, Latifa Karim, Manon Deckers, Martin J.B. Taphoorn, Melissa Kerkhof, Astrid Weyerbrock, Marc Sanson, Ann Hoeben, Slávka Lukacova, Lombardi Giuseppe, Sieger Leenstra, Monique Hanse, Ruth E.M. Fleischeuer, Colin Watts, Nicos Angelopoulos, Thierry Gorlia, Vassilis Golfinopoulos, Vincent Bours, Martin J. Van Den Bent, Pierre A. Robe, Pim J. French
Initial Panitumumab Plus Fluorouracil, Leucovorin, and Oxaliplatin or Plus Fluorouracil and Leucovorin in Elderly Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The PANDA Trial by the GONO FoundationJOURNAL OF CLINICAL ONCOLOGY45,40Lonardi Sara, Cosimo Rasola, Riccardo Lobefaro, Daniele Rossini, Vincenzo Formica, Mario Scartozzi, Giovanni Luca Frassineti, Giorgia Boscolo, Saverio Cinieri, Samantha Di Donato, Nicoletta Pella, Bergamo Francesca, Alessandra Raimondi, Ermenegildo Arnoldi, Lorenzo Antonuzzo, Cristina Granetto, Fable Zustovich, Monica Ronzoni, Silvana Leo, Federica Morano, F. Loupakis, Buggin Federica, Vittorina Zagonel, Fassan Matteo, Chiara Cremolini, Luca Boni, Filippo Pietrantonio
Nine-Week Versus One-Year Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 10-Year Update of the ShortHER Phase III Randomized TrialJOURNAL OF CLINICAL ONCOLOGY45,40Pierfranco Conte, Giancarlo Bisagni, Federico Piacentini, Samanta Sarti, Santino Minichillo, Elisa Anselmi, Michele Aieta, Vittorio Gebbia, Alessio Schirone, Antonino Musolino, Ornella Garrone, Alessandra Beano, Anita Rimanti, Francesco Giotta, Anna Turletti, Miglietta Federica, Dieci Maria Vittoria, Roberto Vicini, Sara Balduzzi, Robert D’Amico, Guarneri Valentina
Pathologic Complete Response and Individual Patient Prognosis After Neoadjuvant Chemotherapy Plus Anti-Human Epidermal Growth Factor Receptor 2 Therapy of Human Epidermal Growth Factor Receptor 2-Positive Early Breast CancerJOURNAL OF CLINICAL ONCOLOGY45,40Marion T. Van Mackelenbergh, Sibylle Loibl, Michael Untch, Marc Buyse, Charles E. Geyer, Luca Gianni, Andreas Schneeweiss, Pierfranco Conte, Martine Piccart, Herve Bonnefoi, Christian Jackisch, Valentina Nekljudova, Gong Tang, Pinuccia Valagussa, Colin Neate, Richard Gelber, Coralie Poncet, Pierre Squifflet, Everardo D. Saad, Dominik Heinzmann, Carsten Denkert, Priya Rastogi, Javier Cortes, Guarneri Valentina, Evandro De Azambuja, David Cameron, Gustavo Ismael, Norman Wolmark, Patricia Cortazar
Re-Evaluation of Pathologic Complete Response as a Surrogate for Event-Free and Overall Survival in Human Epidermal Growth Factor Receptor 2-Positive, Early Breast Cancer Treated With Neoadjuvant Therapy Including Anti-Human Epidermal Growth Factor Receptor 2 TherapyJOURNAL OF CLINICAL ONCOLOGY45,40Pierre Squifflet, Everardo D. Saad, Sibylle Loibl, Marion T. Van Mackelenbergh, Michael Untch, Priya Rastogi, Luca Gianni, Andreas Schneeweiss, Pierfranco Conte, Martine Piccart, Hervé Bonnefoi, Christian Jackisch, Valentina Nekljudova, Gong Tang, Pinuccia Valagussa, Colin Neate, Richard Gelber, Coralie Poncet, Dominik Heinzmann, Carsten Denkert, Charles E. Geyer, Javier Cortes, Guarneri Valentina, Evandro De Azambuja, David Cameron, Gustavo Ismael, Norman Wolmark, Patricia Cortazar, Marc Buyse
White Matter Tract Density Index Prediction Model of Overall Survival in GlioblastomaJAMA NEUROLOGY29,00Alessandro Salvalaggio, Lorenzo Pini, Matteo Gaiola, Aron Velco, Giulio Sansone, Mariagiulia Anglani, Lucius Fekonja, Franco Chioffi, Thomas Picht, Michel Thiebaut De Schotten, Vittorina Zagonel, Lombardi Giuseppe, Domenico D¿Avella, Maurizio Corbetta
European Association of Urology Biochemical Recurrence Risk Classification as a Decision Tool for Salvage Radiotherapy – A Multicenter StudyEUROPEAN UROLOGY23,40Felix Preisser, Raisa S. Abrams-Pompe, Piter Jan Stelwagen, Dirk Böhmer, Fabio Zattoni, Alessandro Magli, Juan Gómez Rivas, Roser Vives Dilme, Sepulcri Matteo, Aritz Eguibar, Isabel Heidegger, Christoph Arnold, Christian D. Fankhauser, Felix K.-H. Chun, Henk Van Der Poel, Giorgio Gandaglia, Thomas Wiegel, Roderick C.N. Van Den Bergh, Derya Tilki
Robot-assisted Radical Cystectomy with Orthotopic Neobladder Reconstruction: Techniques and Functional Outcomes in MalesEUROPEAN UROLOGY23,40Alberto Martini, Ugo Giovanni Falagario, Antonio Russo, Laura S. Mertens, Luca Di Gianfrancesco, Carlo Andrea Bravi, Jonathan Vollemaere, Muhammad Abdeen, Mikolaj Mendrek, Eirik Kjøbli, Stephan Buse, Carl Wijburg, Alae Touzani, Guillaume Ploussard, Alessandro Antonelli, Laura Schwenk, Jan Ebbing, Nikhil Vasdev, Gabriel Froelicher, Hubert John, Abdullah Erdem Canda, Mevlana Derya Balbay, Marcel Stoll, Sebastian Edeling, Jorn H. Witt, Sami-Ramzi Leyh-Bannurah, Stefan Siemer, Michael Stoeckle, Alexander Mottrie, Frederiek D’Hondt, Crestani Alessandro, Porreca Angelo, Hendrik Van Der Poel, Karel Decaestecker, Richard Gaston, N. Peter Wiklund, Abolfazl Hosseini
The Akt/mTOR and MNK/eIF4E pathways rewire the prostate cancer translatome to secrete HGF, SPP1 and BGN and recruit suppressive myeloid cellsNATURE CANCER22,70Daniela Brina, Adele Ponzoni, Martina Troiani, Bianca Calì, Emiliano Pasquini, Giuseppe Attanasio, Simone Mosole, Michela Mirenda, Mariantonietta D¿Ambrosio, Manuel Colucci, Ilaria Guccini, Ajinkya Revandkar, Abdullah Alajati, Toma Tebaldi, Deborah Donzel, Fabio Lauria, Nahjme Parhizgari, Aurora Valdata, Martino Maddalena, Arianna Calcinotto, Marco Bolis, Andrea Rinaldi, Simon Barry, Jan Hendrik Rüschoff, Sabbadin Marianna, Semini Sumanasuriya, Mateus Crespo, Adam Sharp, Wei Yuan, Mathew Grinu, Alexandra Boyle, Cynthia Miller, Lloyd Trotman, Nicolas Delaleu, Fassan Matteo, Holger Moch, Gabriella Viero, Johann De Bono, Andrea Alimonti

Top 15 pubblicazioni linea 3 anno 2022
TitoloTestataIF grezzoAutori
Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trialNATURE MEDICINE87,24Andrea Sartore-Bianchi, Filippo Pietrantonio, Lonardi Sara, Benedetta Mussolin, Francesco Rua, Giovanni Crisafulli, Alice Bartolini, Elisabetta Fenocchio, Alessio Amatu, Paolo Manca, bergamo francesca, Federica Tosi, Gianluca Mauri, Margherita Ambrosini, Daniel Francesca, Valter Torri, Angelo Vanzulli, Daniele Regge, Giovanni Cappello, Caterina Marchiò, Enrico Berrino, Anna Sapino, Silvia Marsoni, Salvatore Siena, Alberto Bardelli
RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAF V600E metastatic colorectal cancerNATURE MEDICINE87,24Elena Elez, Javier Ros, Jose Fernández, Guillermo Villacampa, Ana Belén Moreno-Cárdenas, Carlota Arenillas, Kinga Bernatowicz, Raquel Comas, Shanshan Li, David Philip Kodack, Roberta Fasani, Ariadna Garcia, Javier Gonzalo-Ruiz, Alejandro Piris-Gimenez, Paolo Nuciforo, Grainne Kerr, Intini Rossana, Montagna Aldo, Marco Maria Germani, Giovanni Randon, Ana Vivancos, Ron Smits, Diana Graus, Raquel Perez-Lopez, Chiara Cremolini, Lonardi Sara, Filippo Pietrantonio, Rodrigo Dienstmann, Josep Tabernero, Rodrigo A. Toledo
Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trialLANCET ONCOLOGY54,43Carlotta Antoniotti, Daniele Rossini, Filippo Pietrantonio, Aurélie Catteau, Lisa Salvatore, Lonardi Sara, Isabelle Boquet, Stefano Tamberi, Federica Marmorino, Roberto Moretto, Margherita Ambrosini, Emiliano Tamburini, Giampaolo Tortora, Alessandro Passardi, bergamo francesca, Alboukadel Kassambara, Thomas Sbarrato, Federica Morano, Giuliana Ritorto, Beatrice Borelli, Alessandra Boccaccino, Veronica Conca, Mirella Giordano, Clara Ugolini, Jacques Fieschi, Alexia Papadopulos, Clémentine Massoué, Giuseppe Aprile, Lorenzo Antonuzzo, Fabio Gelsomino, Erika Martinelli, Nicoletta Pella, Gianluca Masi, Gabriella Fontanini, Luca Boni, Jérôme Galon, Chiara Cremolini
Is upfront full molecular profiling needed in all patients with colorectal cancer in daily practice?LANCET ONCOLOGY54,43Rodrigo Dienstmann, Lonardi Sara
Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II TrialJOURNAL OF CLINICAL ONCOLOGY50,74Paolo A. Ascierto, Mario Mandalà, Pier Francesso Ferrucci, Massimo Guidoboni, Piotr Rutkowski, Virginia Ferraresi, Ana Arance, Michele Guida, Evaristo Maiello, Helen Gogas, Erika Richtig, Maria Teresa Fierro, Celeste Lebbè, Hildur Helgadottir, Paola Queirolo, Francesco Spagnolo, Marco Tucci, Michele Del Vecchio, Maria Gonzales Cao, Alessandro Marco Minisini, Sabino De Placido, Miguel F. Sanmamed, Domenico Mallardo, Marcello Curvietto, Ignacio Melero, Giuseppe Palmieri, Antonio M. Grimaldi, Diana Giannarelli, Reinhard Dummer, chiarion sileni vanna
Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With RAS/BRAF Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONOJOURNAL OF CLINICAL ONCOLOGY50,74Daniele Rossini, Carlotta Antoniotti, Lonardi Sara, Filippo Pietrantonio, Roberto Moretto, Lorenzo Antonuzzo, Alessandra Boccaccino, Federica Morano, Marco Brugia, Carmelo Pozzo, Federica Marmorino, bergamo francesca, Emiliano Tamburini, Alessandro Passardi, Giovanni Randon, Murgioni Sabina, Beatrice Borelli, Angela Buonadonna, Mirella Giordano, Gabriella Fontanini, Veronica Conca, Vincenzo Formica, Massimo Aglietta, Roberto Bordonaro, Giuseppe Aprile, Gianluca Masi, Luca Boni, Chiara Cremolini
Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O6-Methylguanine-DNA Methyltransferase-Silenced Metastatic Colorectal Cancer: The MAYA TrialJOURNAL OF CLINICAL ONCOLOGY50,74Federica Morano, Alessandra Raimondi, Filippo Pagani, Lonardi Sara, Lisa Salvatore, Chiara Cremolini, Murgioni Sabina, Giovanni Randon, Federica Palermo, Lorenzo Antonuzzo, Nicoletta Pella, Patrizia Racca, Michele Prisciandaro, Monica Niger, Francesca Corti, bergamo francesca, Alberto Zaniboni, Margherita Ratti, Michele Palazzo, Celeste Cagnazzo, Maria Alessandra Calegari, Federica Marmorino, Iolanda Capone, Elena Conca, Adele Busico, Silvia Brich, Elena Tamborini, Federica Perrone, Massimo Di Maio, Massimo Milione, Maria Di Bartolomeo, Filippo De Braud, Filippo Pietrantonio
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant TrialsJOURNAL OF CLINICAL ONCOLOGY50,74Claire Gallois, Qian Shi, Jeffrey Meyers, Lonardi Sara, Greg Yothers, Julien Taieb
Activity of Cabazitaxel in Metastatic or Inoperable Locally Advanced Dedifferentiated Liposarcoma: A Phase 2 Study of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG)JAMA Oncology33,01Roberta Sanfilippo, Richard L. Hayward, Jammbe Musoro, Charlotte Benson, Michael Gordon Leahy, Brunello Antonella, Jean-Yves Blay, Neeltje Steeghs, Ingrid M. E. Desar, Nasim Ali, Alice Hervieu, Khin Thway, Sandrine Marreaud, Saskia Litiere, Bernd Kasper
Autoimmune gastritis: Long-Term natural history in naïve Helicobacter pylori-negative patientsGUT31,80Massimo Rugge, Ludovica Bricca, Stefano Guzzinati, Diana Sacchi, Marco Pizzi, Edoardo Savarino, Fabio Farinati, Manuel Zorzi, FASSAN MATTEO, Angelo Paolo Dei Tos, Peter Malfertheiner, Robert M Genta, David Y Graham
A Novel Benchmarking Approach to Assess the Agreement among Radiomic ToolsRADIOLOGY29,15Bettinelli Andrea, MARTURANO FRANCESCA, Michele Avanzo, Emiliano Loi, Enrico Menghi, Emilio Mezzenga, Giovanni Pirrone, Anna Sarnelli, Lidia Strigari, Silvia Strolin, paiusco marta
Ibrutinib improves survival compared with chemotherapy in mantle cell lymphoma with central nervous system relapseBLOOD25,67Chiara Rusconi, Chan Y. Cheah, Toby A. Eyre, David Tucker, Pavel Klener, Eva Giné, Lara Crucitti, Cristina Muzi, Sara Iadecola, Gabriele Infante, Sophie Bernard, Rebecca L. Auer, Chiara Pagani, Monika Duglosz-Danecka, Heidi Mocikova, Tom van Meerten, Emanuele Cencini, Ana Marin-Niebla, Michael E. Williams, Piera Angelillo, Paolo Nicoli, Annalisa Arcari, Lucia Morello, Donato Mannina, Orsola Vitagliano, Sartori Roberto, Annalisa Chiappella, Roberta Sciarra, Piero M. Stefani, Martin Dreyling, John F. Seymour, Carlo Visco
Addition of Niraparib to Best Supportive Care as Maintenance Treatment in Patients with Advanced Urothelial Carcinoma Whose Disease Did Not Progress After First-line Platinum-based Chemotherapy: The Meet-URO12 Randomized Phase 2 TrialEUROPEAN UROLOGY24,34Francesca Vignani, Rosa Tambaro, Ugo De Giorgi, Patrizia Giannatempo, Bimbatti Davide, Claudia Carella, Marco Stellato, Francesco Atzori, Michele Aieta, Cristina Masini, Alketa Hamzaj, Paola Ermacora, Antonello Veccia, Giuseppa Scandurra, Teresa Gamba, Gianluca Ignazzi, Sandro Pignata, Marilena Di Napoli, Cristian Lolli, Giuseppe Procopio, Pierantoni Francesco, Antonia Zonno, Daniele Santini, Massimo Di Maio
Addition of Bevacizumab to Erlotinib as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous NSCLC: The BEVERLY Multicenter Randomized Phase 3 TrialJournal of Thoracic Oncology20,12Maria Carmela Piccirillo, Bonanno Laura, Marina Chiara Garassino, Giovanna Esposito, Claudio Dazzi, Luigi Cavanna, Marco Angelo Burgio, Francesco Rosetti, Simona Rizzato, Floriana Morgillo, Saverio Cinieri, Antonello Veccia, Maximilan Papi, Giuseppe Tonini, Vittorio Gebbia, Serena Ricciardi, Daniele Pozzessere, FERRO ALESSANDRA, Claudia Proto, Raffaele Costanzo, Manolo D’Arcangelo, Manuela Proietto, Piera Gargiulo, Raimondo Di Liello, Laura Arenare, Filippo De Marinis, Lucio Crinò, Fortunato Ciardiello, Nicola Normanno, Ciro Gallo, Francesco Perrone, Cesare Gridelli, Alessandro Morabito
Bevacizumab-induced hypertension as a predictor of clinical outcome in metastatic colorectal cancer: An individual patient data-based pooled analysis of two randomized studies and a systematic review of the literatureCANCER TREATMENT REVIEWS13,61Pasquale Lombardi, Daniele Rossini, Veronica Crespi, Marco Maria Germani, bergamo francesca, Filippo Pietrantonio, Daniele Santini, Giacomo Allegrini, Daniel Francesca, Filippo Pagani, Carlotta Antoniotti, Alberto Zaniboni, Veronica Conca, Tiziana Pia Latiano, Alessandra Boccaccino, Alessandro Passardi, Emiliano Tamburini, Gianluca Masi, Massimo Di Maio, Chiara Cremolini

Last modified: 03/07/2024 12:01

Scroll to Top